1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
3.8. Products in Pipeline
4. TECHNOLOGICAL OUTLOOK
5. REGENERATIVE STEM CELL THERAPY MARKET BY TYPE
5.1. Introduction
5.2. Pluripotent Stem Cells
5.3. Adult Stem Cells
6. REGENERATIVE STEM CELL THERAPY MARKET BY APPLICATION
6.1. Introduction
6.2. Musculoskeletal Disorder
6.3. Neurological Disorder
6.4. Cardiovascular Disease
6.5. Oncology
6.6. Orthopedics
6.7. Others
7. REGENERATIVE STEM CELL THERAPY MARKET BY END-USER
7.1. Introduction
7.2. Hospitals
7.3. Specialty Clinics
7.4. Research & Academic Institute
7.5. Others
8. REGENERATIVE STEM CELL THERAPY MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. USA
8.2.2. Canada
8.2.3. Mexico
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Others
8.4. Europe
8.4.1. Germany
8.4.2. France
8.4.3. United Kingdom
8.4.4. Spain
8.4.5. Others
8.5. Middle East and Africa
8.5.1. Saudi Arabia
8.5.2. UAE
8.5.3. Others
8.6. Asia Pacific
8.6.1. China
8.6.2. India
8.6.3. Japan
8.6.4. South Korea
8.6.5. Indonesia
8.6.6. Thailand
8.6.7. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. Mesoblast Ltd
10.2. Vericel Corporation
10.3. Organogenesis Holdings Inc.
10.4. Globus Medical Inc.
10.5. Medipost Co., Ltd.
10.6. Anterogen Co., Ltd.
10.7. Jcr Pharmaceuticals Co., Ltd.
10.8. Athersys, Inc.
10.9. CRISPR Therapeutics
10.10. Fate Therapeutics
11. APPENDIX
11.1. Currency
11.2. Assumptions
11.3. Base and Forecast Years Timeline
11.4. Key benefits for the stakeholders
11.5. Research Methodology
11.6. Abbreviations
LIST OF FIGURES
LIST OF TABLES